Alphamab Oncology Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	166.34	-210.59	-325.72	-412.42
Depreciation & Amortization	77.03	69.12	55.19	41.1
Loss (Gain) From Sale of Assets	0.25	0.1	0.01	-
Stock-Based Compensation	2.53	5.72	13.29	8.17
Other Operating Activities	-46.93	-75.19	-82.62	5.17
Change in Accounts Receivable	-9.39	8.36	-7.88	-7.61
Change in Inventory	-3.06	-14.11	-6.73	-13.59
Change in Accounts Payable	8.56	1.26	31.09	44.71
Change in Unearned Revenue	13.86	-3.05	1.93	15.12
Change in Other Net Operating Assets	3.15	15.55	21.14	-1.25
Operating Cash Flow	212.34	-202.84	-300.31	-320.6
Capital Expenditures	-21.77	-36.18	-129.65	-158.12
Sale of Property, Plant & Equipment	0.22	-	-	-
Investment in Securities	-139.34	-39.52	946.14	664.22
Other Investing Activities	67.97	57.6	34.26	68.16
Investing Cash Flow	-92.93	-18.11	850.76	574.26
Long-Term Debt Issued	127.25	465	401.07	692.47
Total Debt Issued	127.25	465	401.07	692.47
Long-Term Debt Repaid	-207.93	-552.89	-692.95	-313.97
Total Debt Repaid	-207.93	-552.89	-692.95	-313.97
Net Debt Issued (Repaid)	-80.68	-87.89	-291.88	378.5
Issuance of Common Stock	0.14	329.43	0.25	0.35
Repurchase of Common Stock	-9.19	-	-	-
Other Financing Activities	-9.23	-23.46	-19.28	-14.94
Financing Cash Flow	-98.96	218.07	-310.9	363.9
Foreign Exchange Rate Adjustments	5.69	19.67	26.34	0.42
Net Cash Flow	26.13	16.8	265.88	617.99
Free Cash Flow	190.56	-239.02	-429.96	-478.72
Free Cash Flow Margin	29.77%	-109.26%	-257.70%	-327.84%
Free Cash Flow Per Share	0.19	-0.25	-0.46	-0.51
Cash Interest Paid	9.23	11.32	19.28	14.94
Levered Free Cash Flow	139.12	-186.64	-332.02	-330.88
Unlevered Free Cash Flow	145.32	-179.02	-323.14	-322.64
Change in Working Capital	13.12	8.01	39.55	37.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.